Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max S Topp

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Blood Cancer Journal|July 30, 2025
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Blood Cancer Journal|November 1, 2025
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
The New England Journal of Medicine|March 2, 2017
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaHagop Kantarjian, Anthony Stein, Nicola Gökbuget, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Leukemia|October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaMichael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 26, 2022
Virus variant-specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022Isabell Wagenhäuser, Kerstin Knies, Daniela Hofmann, et al.
Deutsches Arzteblatt International|December 5, 2023
The Sensitivity of Rapid Tests for SARS-CoV-2 AntigenKerstin Knies, Isabell Wagenhäuser, Daniela Hofmann, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Blood Cancer Journal|July 30, 2025
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Blood Cancer Journal|November 1, 2025
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
The New England Journal of Medicine|March 2, 2017
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaHagop Kantarjian, Anthony Stein, Nicola Gökbuget, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Advances|April 23, 2025
Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myelomaJan Hendrik Frenking, Xiang Zhou, Kai Rejeski, et al.
Leukemia|October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaMichael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 26, 2022
Virus variant-specific clinical performance of SARS coronavirus two rapid antigen tests in point-of-care use, from November 2020 to January 2022Isabell Wagenhäuser, Kerstin Knies, Daniela Hofmann, et al.
Deutsches Arzteblatt International|December 5, 2023
The Sensitivity of Rapid Tests for SARS-CoV-2 AntigenKerstin Knies, Isabell Wagenhäuser, Daniela Hofmann, et al.
Pageof 13